Результаты поиска

PB2575: HIGH INCIDENCE OF RESPIRATORY TRACT INFECTIONS FOLLOWING COVID-19 WAVES IN PATIENTS WITH PLASMA CELL DYSCRASIAS

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Charlson Comorbidity Index, respectively. 13 (48%) pts underwent I line in different phases of therapy: 7 Daratumumab (Dara)-bortezomib-thalidomide and dexamethasone(D), 2 autologous stem cell transplant (SCT) with Melphalan200 and 4 lenalidomide maintenance. 7 (26%) pts were in II line treated with triplets …

Реальная эффективность обслуживания бортезомиба после введения VMP в санитарную миелому: целевое экспериментальное исследование эмуляции.

Bortezomib-melphalan-prednisone (VMP) — установленный вводный режим для сноса трансплантации, недавно диагностированный несколькими миеломами (NDMM), однако оптимальные стратегии после введения остаются неясными. В ходе этого исследования была проведена оценка эффективности обслуживания бортезомибной системы с использованием пробной эмуляции мишеней. Мы сравнили предполагаемую группу поддержки.KMMWP-174 ) с внешней контрольной когортой из многоцентрового реестра. Число пациентов, прошедших курс лечения 9 Циклы VMP, полученные ≥ частичная реакция и без движения 60 днями. Индексом была дата нача

Совпадение в полном тексте источника
… In Korea, VMP continues to be frequently used, particularly for elderly patients and those with renal impairment or elevated thrombotic risk, for whom lenalidomide-based triplets may be contraindicated or less feasible. … Elderly patients with comorbidities may be unsuitable for intensive triplet regimens. Our study addresses whether proteasome inhibitor continuation after VMP provides benefit over observation—a question remaining relevant independent of whether VMP represents optimal initial therapy. …

The role of therapeutic plasma exchange in plasma cell disorders.

Therapeutic plasma exchange (TPE) is an extracorporeal technique where patient's plasma containing pathogenic substances is separated and removed from the whole blood, while the cellular component is returned to the patient mixed with replacement solution via an apheresis machine. Due to its ability to remove pathogenic substances from plasma including immunoglobulins, TPE has proven efficacious in the management of various disorders across different medical disciplines, including plasma cell dyscrasias, which are characterized by the abundant secretion of non-functional immunoglobulins produc

Совпадение в полном тексте источника
… Dimopoulos MA Roussou M Gavriatopoulou M Psimenou E Eleutherakis-Papaiakovou E Migkou M Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis Am J Hematol … 2016 91 5 499 502 10.1002/ajh.24335 26890495 Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M et al (2016) Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients …

Daratumumab плюс VRd в японских пациентах, имеющих право на трансплантацию/отсроченные заболевания NDMM: японская подгруппа по испытанию CEPHEUS.

:: фазы 3 Судебное разбирательство по делу CEPHEUS было проведено в 13 начиная с декабря 11, 2018 в случае пациентов с недавно поставленным диагнозом множественной миеломы (НДММ), которые имели право на трансплантацию или для которых трансплантация не была запланирована в качестве первоначальной терапии. Бортезомиб, линалидомид и дексаметасон (VRd) с даратумумабом (D-VRd) дали более глубокие и долгосрочные ответные меры и снизили риск развития заболеваний или смерти по сравнению с VRd. В ходе этого анализа была проведена оценка эффективности и безопасности D-VRd, в частности в японском поднасе

Непоследовательные определения недопустимости трансплантации в миеломе: систематический обзор.

Высокодозвуковой мелфалан, за которым следует аутологическая трансплантация стволовых клеток (ASCT), является стандартом ухода за имеющими на это право пациентами с недавно поставленным диагнозом множественной миеломы (NDMM). Значительная доля пациентов считается не имеющими права на АЗСТ по причине возраста, соприкасаемости, качества работы и/или слабости. Критерии, определяющие невозможность пересадки, по-прежнему являются непоследовательными и плохо характеризуются. Мы провели систематический обзор, в ходе которого оценивались циклы II, III и IV выборочных контролируемых испытаний (РЦТ) до

Осуществимость консолидации после вводного курса с клеточной терапией BCMA CAR-T в недавно диагностированном миеломе, не поступающей в ASCT: предварительная серия дел.

Антигенная химериковая антигенная терапия (CAR) T клеточная терапия B-клеток (BCMA) продемонстрировала многообещающую эффективность при повторном/изобилии множественной миеломы (MM). Однако доказательства, подтверждающие его использование в более ранних лечебных условиях, по-прежнему ограничены. В настоящем исследовании представлена предварительная серия дел, в которой оценивается практическая возможность применения клеточной терапии BCMA CAR-T в качестве клеточной терапии в период после ввода у недавно диагностированных пациентов с несколькими миеломой (NDMM), которые не перешли к автоматичес

Isatuximab плюс bortezomib, lenalidomide и дексаметазон для новых пациентов с сносной трансплантацией: хрупкий подгруппный анализ испытания IMROZ.

Пациенты с множественной миеломой (ММ), отвечающие критериям слабости, имеют худшие результаты, чем те, которые были определены как нежесткие. Здесь мы представляем пост-специальный анализ IMROZ, глобальный, этап III, исследование с открытой маркировкой isatuximab (Isa) с использованием бортезомиба, линалидомида и дексаметазона (VRd), за которым следует Иса-Рд (N)265) против VRd, за которым следует Rd (N=181) в случае недавно диагностированных пациентов, имеющих право на трансплантацию MM (Ti NDMM), с использованием упрощенной оценки слабости Международной рабочей группы по миеломе (МРГМ). Хот

Практическое руководство по клиническому управлению окулистическими неблагоприятными событиями, связанными с Belantamab Mafodotin для пациентов с повторной/редактированной миеломой: рекомендации Группы экспертов стран Латинской Америки.

Множественная миелома является значительной причиной смертности во всем мире, и, хотя изменения в области лечения в целом улучшили результаты, многие пациенты становятся небрежными к стандартной терапии. В Латинской Америке результаты являются особенно неблагоприятными, что еще больше усугубляется препятствиями на пути доступа и равенства. Belantamab mafodotin — новый антитело-наркоманный матрос, направленный против анти-B-клеток антигена. Two недавно фазы 3 - судебные разбирательства, DREAMM-7 и DREAMM-8, продемонстрировали заметную эффективность комбинаций белантамб мафодотина у пациентов с

Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma.

Lenalidomide, ixazomib, and daratumumab have been proposed as maintenance therapies for patients with newly diagnosed multiple myeloma (MM; NDMM). There are, however, no randomized controlled trials (RCTs) comparing them. We conducted a network meta-analysis (NMA) of RCTs comparing these agents against placebo in NDMM. A Bayesian NMA model was used to assess the relative effects of competing treatments on progression-free survival (PFS) and overall survival (OS) in 9 studies including 4115 patients with transplant-eligible MM (TEMM) and 1689 patients with non-transplant-eligible MM (NTEMM). Le

Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis.

Patients with multiple myeloma (MM) who experience early relapse within 12 months of therapy initiation are considered functional high-risk and represent an unmet need, needing better therapies to improve outcomes. The final IKEMA (clinicaltrials gov. identifier: NCT03275285) progression-free survival (PFS) analysis confirmed the significant PFS improvement reported at interim analysis with isatuximab (Isa) plus carfilzomib and dexamethasone (Kd; Isa-Kd) versus Kd in patients with relapsed MM (updated median PFS: 35.7 vs. 19.2 months; hazard ratio [HR] =0.58, 95% confidence interval [CI]: 0.42

Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.

Peripheral T-cell lymphomas (PTCLs) are associated with poor prognosis when treated with cytotoxic chemotherapy. We report the findings of a phase 2 study evaluating a chemotherapy-free combination of romidepsin plus lenalidomide as initial treatment for patients with PTCL who were aged >60 years or noncandidates for chemotherapy. Treatment was initiated with romidepsin 10 mg/m2 IV on days 1, 8, and 15 and lenalidomide 25 mg taken orally from days 1 to 21 of 28-day cycle for up to 1 year. The primary objective was overall response rate (ORR). Secondary objectives included safety and survival.

Multiple Myeloma in Patients over 80: A Real World Retrospective Study of First Line Conservative Approach with Bortezomib Dexamethasone Doublet Therapy and Mini-Review of Literature.

Data on octogenarian patients with MM are scarce, and optimal management remains controversial. We report a retrospective cohort of unselected octogenarian patients with NDMM treated with bortezomib dexamethasone (Vd). Seventy-four patients were treated with an initial doublet therapy (Vd regimen, 2−3 cycles, induction). A dose escalation with an adjunction of melphalan or cyclophosphamide was proposed for patients who had an insufficient response after induction and who could tolerate it. In responders, the treatment was continued until progression or a plateau response for 6 months (consolid

Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry.

Although new multiple myeloma (MM) therapies are effective in alleviating some disease-associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health-related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide-bortezomib-dexamethasone [RVd (n = 445)], bortezomib-melphalan-prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect® MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy-M

The Anti-CD38 Antibody Therapy in Multiple Myeloma.

Multiple myeloma (MM) is the second-most common hematologic malignancy after diffuse large B-cell lymphoma. Despite the improvement in response and survival rates following the introduction of novel therapies, only a few patients are cured, and the majority of MM patients experience several relapses and receive multiple lines of treatment. Currently, bortezomib and lenalidomide are the core component of treatment both at the time of diagnosis and at the relapse as well as the new proteasome inhibitors (PIs), such as carfilzomib and ixazomib, and the next-generation immunomodulatory drug, pomal

Совпадение в полном тексте источника
… This approval was based on two randomized phase III studies, that showed superior PFS and ORR using the MoAb-containing triplets daratumumab plus standard-of-care regimens (bortezomib–dexamethasone [CASTOR trial] [ 5 ] or lenalidomide–dexamethasone [POLLUX trial] [ 6 ]. 6. … These triplets appeared to be well tolerated, with the main adverse events being IRRs. …

The beginning of a new therapeutic era in acute myeloid leukemia.

In the field of AML, the early 2000s were shaped by the advent of novel molecular biology technologies including high-throughput sequencing that improved prognostic classification, response evaluation through the quantification of minimal residual disease, and the launch of research on targeted therapies. Our knowledge of leukemogenesis, AML genetic diversity, gene-gene interactions, clonal evolution, and treatment response assessment has also greatly improved. New classifications based on chromosomal abnormalities and gene mutations are now integrated on a routine basis. These considerable ef

Совпадение в полном тексте источника
… Planned or on‐going clinical trials are already comparing this doublet to triplets with small molecule inhibitors or monoclonal antibodies. … Or will triplets eradicate the disease at first line? Which inhibitor will we use in patients with other concomitant targetable mutations, such as FLT3 or TP53? …

Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors.

Treatment of relapsed/refractory multiple myeloma (RRMM) is more complex today due to the availability of novel therapeutic options, mostly applied as combination regimens. immunotherapy options have especially increased substantially, likewise the understanding that patient-, disease- and treatment-related factors should be considered at all stages of the disease. RRMM is based on definitions of the international myeloma working group (IMWG) and includes biochemical progression, such as paraprotein increase, or symptomatic relapse with CRAB criteria (hypercalcemia, renal impairment, anemia, b

Совпадение в полном тексте источника
… Since lung function/FEV1 assessment is used in the diagnostic workup at primary to tertiary centers, likewise, i.e., before intensive treatment such as triplets, quadruplets or ASCT, FEV1-results are often available. … For fit, but not transplant-eligible patients, a triplet combination should be administered including PIs and/or IMiDs and/or mAbs. In general, treatment regimens are preferably switched, rather than repeated. …

Isatuximab: A Review of Its Use in Multiple Myeloma.

Isatuximab (Sarclisa®; isatuximab-irfc in the USA) is an anti-CD38 monoclonal antibody (mAb) approved for use in the treatment of adults with multiple myeloma (MM): in combination with pomalidomide and dexamethasone for those with relapsed and refractory MM (RRMM) who have received ≥ 2 prior therapies, including lenalidomide and a proteasome inhibitor; and in combination with carfilzomib and dexamethasone for those with relapsed MM who have received ≥ 1 prior therapy. In phase III studies, the addition of isatuximab to pomalidomide and dexamethasone significantly prolonged progression-free sur

Risk and Response-Adapted Treatment in Multiple Myeloma.

Myeloma therapeutic strategies have been adapted to patients' age and comorbidities for a long time. However, although cytogenetics and clinical presentations (plasmablastic cytology; extramedullary disease) are major prognostic factors, until recently, all patients received the same treatment whatever their initial risk. No strong evidence allows us to use a personalized treatment according to one cytogenetic abnormality in newly diagnosed myeloma. Retrospective studies showed a benefit of a double autologous transplant in high-risk cytogenetics according to the International Myeloma Working

Совпадение в полном тексте источника
… In a non-eligible ASCT setting, triplets were superior to doublets in the presence of high-risk cytogenetics. … The Myeloma XI trial [ 57 ] showed that sequential treatment with bortezomib, cyclophosphamide, and dexamethasone (VCD) for patients not achieving at least VGPR after IMiD-based triplet induction improved the response rate and PFS. …

Breaking Boundaries: Immunotherapy for Myeloid Malignancies.

Immunotherapy has revolutionized the treatment of myeloid oncologic diseases, particularly for patients resistant to chemotherapy or ineligible for allogeneic stem cell transplantation due to age or fitness constraints. As our understanding of the immunopathogenesis of myeloid malignancies expands, so too do the treatment options available to patients. Immunotherapy in myeloid malignancies, however, faces numerous challenges due to the dynamic nature of the disease, immune dysregulation, and the development of immune evasion mechanisms. This review outlines the progress made in the field of im

Lenalidomide Plus Dexamethasone as FIRST-Line Therapy in Transplant-Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non-Interventional Study FIRST-NIS and Comparison With the FIRST Pivotal Phase III Clinical Trial.

OBJECTIVES: Lenalidomide and low-dose dexamethasone (Rd) is a standard regimen for transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM), for whom a multi-drug treatment regimen is not considered appropriate. While Rd has been intensively investigated in clinical trials, prospective real-world data are still scarce. PATIENTS AND METHODS: The prospective, multicenter, non-interventional study FIRST-NIS (NTC02537808) investigated the effectiveness, safety, and quality of life (QoL) of Rd in a German real-world setting. G8-Geriatric assessment was used to assess patie